1096-8652/asset/cover.gif?v=1&s=d31a603f9c7a1894ee3b68044c6fdcbe64ff8068 "American Journal of Hematology")
Dr. Lalla is no longer employed by Amgen Inc.
1096-8652/asset/olbannerleft.gif?v=1&s=d9288d4b31f0b8e9a1eb2d195cb165e0aa1d7a97)
1096-8652/asset/olbannerright.gif?v=1&s=78488ac502104a3d829e729353def6ce62dc1e29)
Clinical Pearls in Blood Diseases
You have full text access to this OnlineOpen article
Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura
Article first published online: 23 AUG 2007
DOI: 10.1002/ajh.20992
Copyright © 2007 Wiley-Liss, Inc.
Additional Information
How to Cite
McMillan, R., Bussel, J. B., George, J. N., Lalla, D. and Nichol, J. L. (2008), Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am. J. Hematol., 83: 150–154. doi: 10.1002/ajh.20992
Publication History
- Issue published online: 2 JAN 2008
- Article first published online: 23 AUG 2007
- Manuscript Accepted: 9 APR 2007
- Manuscript Revised: 5 APR 2007
- Manuscript Received: 12 JAN 2007
Funded by
- Amgen Inc.
- Abstract
- References
- Cited By
Abstract
Adult chronic immune thrombocytopenic purpura (ITP) is a disorder manifested by varying degrees of purpura and mucosal bleeding, rarely including intracranial hemorrhage. Therapy is aimed at increasing the patient's platelet count to safe levels and includes a wide variety of treatments. While the diagnosis, treatment, and prognosis of chronic ITP have been extensively discussed, the effect of ITP and its treatment on patient quality of life has not been evaluated in adults. In this study, the Short-Form 36 questionnaire was used to evaluate the health-related quality of life (HRQOL) of 73 adult ITP patients compared with that of the general U.S. population and of patients with six other relatively common chronic disorders. This study shows that the HRQOL of adult patients with ITP is significantly worse than that of the general U.S. population. It is also worse than that of patients with hypertension, arthritis, or cancer; similar to that of patients with diabetes; but better than that of patients with congestive heart failure or a missing or paralyzed limb. Future studies need to address the effects of treatment not only on the platelet count and bleeding but also on HRQOL. Am. J. Hematol., 2008. © 2007 Wiley-Liss, Inc.